Scoring system to predict positive peritoneal cytology in patients with resectable and borderline resectable pancreatic cancer.
cytology
pancreatic cancer
risk factor
scoring system
staging laparoscopy
Journal
Journal of hepato-biliary-pancreatic sciences
ISSN: 1868-6982
Titre abrégé: J Hepatobiliary Pancreat Sci
Pays: Japan
ID NLM: 101528587
Informations de publication
Date de publication:
12 May 2024
12 May 2024
Historique:
revised:
26
02
2024
received:
20
11
2023
accepted:
11
03
2024
medline:
13
5
2024
pubmed:
13
5
2024
entrez:
13
5
2024
Statut:
aheadofprint
Résumé
The aim of this study was to evaluate factors to predict positive peritoneal cytology, whcih would determine the indication for staging laparoscopy in pancreatic cancer. A total of 430 patients that underwent pancreatectomy for resectable and borderline resectable pancreatic cancer were retrospectively reviewed. Among 430 patients, 36 had positive cytology (8.4%). Median survival time in negative cytology was 24.7 months, compared with 15.1 months in positive cytology (p = .004). Factors to predict positive cytology in pancreatic cancer according to multivariate analysis were tumor location (body, tail; OR 2.66; 95% CI: 1.21-5.85; p = .015), tumor size ≥30 mm (OR 2.95; 95% CI: 1.35-6.47; p = .007) and radiographic other-organ invasion (HR 2.79; 95% CI: 1.01-7.67; p = .047). Patients were scored 0 to 3 corresponding with these factors. Rates of positive cytology increases in each score were: score 0: 2.9%, score 1: 6.7%, score 2: 18.3%, score 3: 36.8%. Tumor location (body or tail), tumor size ≥30 mm, and radiographic other-organ invasions were risk factors for positive cytology in pancreatic cancer. This scoring system might be a useful indicator to perform staging laparoscopy to diagnose positive cytology.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this study was to evaluate factors to predict positive peritoneal cytology, whcih would determine the indication for staging laparoscopy in pancreatic cancer.
METHODS
METHODS
A total of 430 patients that underwent pancreatectomy for resectable and borderline resectable pancreatic cancer were retrospectively reviewed.
RESULTS
RESULTS
Among 430 patients, 36 had positive cytology (8.4%). Median survival time in negative cytology was 24.7 months, compared with 15.1 months in positive cytology (p = .004). Factors to predict positive cytology in pancreatic cancer according to multivariate analysis were tumor location (body, tail; OR 2.66; 95% CI: 1.21-5.85; p = .015), tumor size ≥30 mm (OR 2.95; 95% CI: 1.35-6.47; p = .007) and radiographic other-organ invasion (HR 2.79; 95% CI: 1.01-7.67; p = .047). Patients were scored 0 to 3 corresponding with these factors. Rates of positive cytology increases in each score were: score 0: 2.9%, score 1: 6.7%, score 2: 18.3%, score 3: 36.8%.
CONCLUSIONS
CONCLUSIONS
Tumor location (body or tail), tumor size ≥30 mm, and radiographic other-organ invasions were risk factors for positive cytology in pancreatic cancer. This scoring system might be a useful indicator to perform staging laparoscopy to diagnose positive cytology.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Japanese Society of Hepato‐Biliary‐Pancreatic Surgery.
Références
Li GZ, Doherty GM, Wang J. Surgical Management of Gastric Cancer: a review. JAMA Surg. 2022;157(5):446–454.
Passot G, Mohkam K, Cotte E, Glehen O. Intra‐operative peritoneal lavage for colorectal cancer. World J Gastroenterol. 2014;20(8):1935–1939.
Yamada S, Takeda S, Fujii T, Nomoto S, Kanazumi N, Sugimoto H, et al. Clinical implications of peritoneal cytology in potentially resectable pancreatic cancer: positive peritoneal cytology may not confer an adverse prognosis. Ann Surg. 2007;246(2):254–258.
Yamada S, Fujii T, Kanda M, Sugimoto H, Nomoto S, Takeda S, et al. Value of peritoneal cytology in potentially resectable pancreatic cancer. Br J Surg. 2013;100(13):1791–1796.
Yoshioka R, Saiura A, Koga R, Arita J, Takemura N, Ono Y, et al. The implications of positive peritoneal lavage cytology in potentially resectable pancreatic cancer. World J Surg. 2012;36(9):2187–2191.
Ferrone CR, Haas B, Tang L, Coit DG, Fong Y, Brennan MF, et al. The influence of positive peritoneal cytology on survival in patients with pancreatic adenocarcinoma. J Gastrointest Surg. 2006;10(10):1347–1353.
Satoi S, Murakami Y, Motoi F, Uemura K, Kawai M, Kurata M, et al. Reappraisal of peritoneal washing cytology in 984 patients with pancreatic ductal adenocarcinoma who underwent margin‐negative resection. J Gastrointest Surg. 2015;19(1):6–14.
Cao F, Li J, Li A, Li F. Prognostic significance of positive peritoneal cytology in resectable pancreatic cancer: a systemic review and meta‐analysis. Oncotarget. 2017;8(9):15004–15013.
Aoki S, Mizuma M, Hayashi H, Yoshimachi S, Hata T, Miura T, et al. Prognostic impact of intraoperative peritoneal cytology after neoadjuvant therapy for potentially resectable pancreatic cancer. Pancreatology. 2020;20(8):1711–1717.
Sakoda T, Uemura K, Kondo N, Sumiyoshi T, Okada K, Seo S, et al. Prognostic value of peritoneal lavage cytology in patients with pancreatic ductal adenocarcinoma stratified by the Resectability status. J Gastrointest Surg. 2021;25(11):2871–2880.
National Comprehensive Cancer Network. NCCN practice guidelines for pancreatic cancer, Version 1. 2023.
Satoi S, Yanagimoto H, Yamamoto T, Toyokawa H, Hirooka S, Yamaki S, et al. A clinical role of staging laparoscopy in patients with radiographically defined locally advanced pancreatic ductal adenocarcinoma. World J Surg Oncol. 2016;14(1):14.
Sell NM, Fong ZV, Del Castillo CF, Qadan M, Warshaw AL, Chang D, et al. Staging laparoscopy not only saves patients an incision, but may also help them live longer. Ann Surg Oncol. 2018;25(4):1009–1016.
Jimenez RE, Warshaw AL, Fernandez‐Del CC. Laparoscopy and peritoneal cytology in the staging of pancreatic cancer. J Hepatobiliary Pancreat Surg. 2000;7(1):15–20.
Hariharan D, Constantinides VA, Froeling FE, Tekkis PP, Kocher HM. The role of laparoscopy and laparoscopic ultrasound in the preoperative staging of pancreatico‐biliary cancers – a meta‐analysis. Eur J Surg Oncol. 2010;36(10):941–948.
Brierley JD, Gospodarowicw MK, Wittekind C. TNM classification of malignant Tumours. 8th ed. Switzerland: Wiley‐Blackwell; 2017.
Strobel O, Hank T, Hinz U, Bergmann F, Schneider L, Springfield C, et al. Pancreatic cancer surgery: the new R‐status counts. Ann Surg. 2017;265(3):565–573.
Hirono S, Kawai M, Okada KI, Miyazawa M, Shimizu A, Kitahata Y, et al. Treatment strategy for borderline resectable pancreatic cancer with radiographic artery involvement. Pancreas. 2016;45(10):1438–1446.
Yamaue H, Satoi S, Kanbe T, Miyazawa M, Tani M, Kawai M, et al. Phase II clinical study of alternate‐day oral therapy with S‐1 as first‐line chemotherapy for locally advanced and metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2014;73(1):97–102.
Okada K, Kawai M, Hirono S, Satoi S, Yanagimoto H, Ioka T, et al. Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial. Cancer Chemother Pharmacol. 2016;78(4):719–726.
Okada KI, Hirono S, Kawai M, Miyazawa M, Shimizu A, Kitahata Y, et al. Phase I study of nab‐paclitaxel plus gemcitabine as neoadjuvant therapy for borderline Resectable pancreatic cancer. Anticancer Res. 2017;37(2):853–858.
Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long‐term outcomes among patients with resected pancreatic cancer: the CONKO‐001 randomized trial. Jama. 2013;310(14):1473–1481.
Uesaka K, Boku N, Fukutomi A, Okamura Y, KKonishi M, Matsumoto I, et al. Adjuvant chemotherapy of S‐1 versus gemcitabine for resected pancreatic cancer: a phase 3, open‐label, randomised, non‐inferiority trial (JASPAC 01). Lancet. 2016;388(10041):248–257.
Tani M, Kawai M, Terasawa H, Ina H, Hirono S, Uchiyama K, et al. Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer? J Surg Oncol. 2006;93(6):485–490.
Sakaguchi T, Satoi S, Hashimoto D, Yamamoto T, Yamaki S, Hirooka S, et al. A simple risk score for detecting radiological occult metastasis in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci. 2022;29(2):262–270.
Takadate T, Morikawa T, Ishida M, Aoki S, Hata T, Iseki M, et al. Staging laparoscopy is mandatory for the treatment of pancreatic cancer to avoid missing radiologically negative metastases. Surg Today. 2021;51(5):686–694.
De Rosa A, Cameron IC, Gomez D. Indications for staging laparoscopy in pancreatic cancer. HPB (Oxford). 2016;18(1):13–20.
Karabicak I, Satoi S, Yanagimoto H, Yamamoto T, Hirooka S, Yamaki S, et al. Risk factors for latent distant organ metastasis detected by staging laparoscopy in patients with radiologically defined locally advanced pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci. 2016;23(12):750–755.
Ariake K, Mizuma M, Motoi F, Maeda S, Morikawa T, Ishida M, et al. Preceding systemic chemotherapy for patients with pancreatic ductal adenocarcinoma with positive peritoneal cytology provides survival benefit compared with up‐front surgery. Ann Surg Oncol. 2021;28(11):6246–6254.
Tsuchida H, Fujii T, Mizuma M, Satoi S, Igarashi H, Eguchi H, et al. Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: a nationwide, cancer registry‐based study from the Japan pancreas society. Surgery. 2019;166(6):997–1003.